News
BCRX
7.55
+2.03%
0.15
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and NewAmsterdam Pharma Company (NAMS)
TipRanks · 3d ago
Weekly Report: what happened at BCRX last week (0715-0719)?
Weekly Report · 4d ago
Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
BioCryst Pharmaceuticals, Inc. Develops complement-mediated and rare disease treatments. The company relies heavily on Orladeyo, which represents 95.8% of its total revenues. The drug's FDA approval and international expansion drive BCRX's revenue growth. Despite high leverage, BCRx has a reasonable pathway to deleveraging through Orladesyo's future growth.
Seeking Alpha · 5d ago
BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
NASDAQ · 07/18 16:00
Weekly Report: what happened at BCRX last week (0708-0712)?
Weekly Report · 07/15 09:03
The five-year returns have been strong for BioCryst Pharmaceuticals (NASDAQ:BCRX) shareholders despite underlying losses increasing
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) share price has soared 102% in the last half decade. The stock has added US$130m to its market cap in the past week. The company has grown revenue at a rate of 51% per year over the last decade. Long term shareholders have made a gain of 15% on average over the same period. BioCryst pharmaceuticals seems like a high growth stock for growth investors.
Simply Wall St · 07/12 13:27
Buy Rating Affirmed for BioCryst Amid Strong Orladeyo Market Penetration and Growth Prospects
TipRanks · 07/12 09:07
ORLADEYO® (BEROTRALSTAT) APPROVED IN PERU
Reuters · 07/09 11:01
How The Pieces Add Up: SMLF Targets $73
NASDAQ · 07/08 14:24
Weekly Report: what happened at BCRX last week (0701-0705)?
Weekly Report · 07/08 09:03
BRIEF-Island Pharmaceuticals Signs Non-Binding Term Sheet With Biocryst
Reuters · 07/03 01:09
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. Granted five newly-hired employees stock options to purchase an aggregate of 46,850 shares. The options and RSUs were granted as of June 28, 2024, as inducements to each employee entering into employment with BioCryst.
Barchart · 07/02 06:00
Weekly Report: what happened at BCRX last week (0624-0628)?
Weekly Report · 07/01 09:03
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
Seeking Alpha · 06/25 18:07
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX), Recursion Pharmaceuticals (RXRX) and Progyny (PGNY)
TipRanks · 06/25 10:01
Weekly Report: what happened at BCRX last week (0617-0621)?
Weekly Report · 06/24 09:03
Insider Stock Buying Reaches US$1.05m On BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. Insiders have bought US$1.0m worth of shares in the last year. The company made a loss during the same period. In the last three months, there's been more insider buying than selling at current prices. BioCryst pharmaceuticals insiders own 1.0% of the company. It's good to see the company has bought shares at close to the current price of US$6.00. You can see the insider transactions of Bio Crystal Pharmaceuticals over the lastyear.
Simply Wall St · 06/20 18:09
Analysts Offer Insights on Healthcare Companies: Standard BioTools (LAB), BioCryst (BCRX) and Alnylam Pharma (ALNY)
TipRanks · 06/20 11:30
Weekly Report: what happened at BCRX last week (0610-0614)?
Weekly Report · 06/17 09:03
BioCryst Shareholders Approve Expansion and Elect Directors
TipRanks · 06/13 21:14
More
Webull provides a variety of real-time BCRX stock news. You can receive the latest news about Biocryst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.